BOLETÍN HTA

HIPERTENSIÓN / 2018 / VOL. 23 44 Referencias 1. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335(8692):765-74. 2. The 1980 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. JAMA Internal Medicine. 1980;140(10):1280-5. 3. Kannel WB. Hypertension: reflections on risks and prognostication. Med Clin North Am. 2009;93(3):541-58, Table of Contents. 4. Marin M. Objetivos terapeuticos en hipertension: las mismas evidencias, diferentes recomendaciones. Revista hipertension arterial. 2014;3(4):3-7. 5. Navarro J. Objetivo del control de la hipertensión arterial. Revista clínica electrónica en atención primaria. 2005(6):1-4. 6. Palacio A. Metas del tratamiento de la hipertension arterial. Revista colombiana de cardiologia. 2007;13(Suplemento 1):209-11. 7. Rollan M, Bedoya M. Cuales son las cifras objetivo de presion arterial en pacientes con diabetes e hipertension. Guia de actualización en diabetes mellitus tipo 2. Ezkurra, P. coordinador. Fundación redGDPS. Badalona: Euromedice Vivactis; 2016. . 2016. 8. Tagle R, Acevedo M. OBJETIVOS TERAPÉUTICOS EN HIPERTENSIÓN ARTERIAL:METAS DE PRESIÓN ARTERIAL EN LOS DIVERSOS SUBGRUPOS DE HIPERTENSOS. Revista Médica Clínica Las Condes. 2018;29(1):21-32. 9. Whelton PK, Carey RM, Aronow WS, Casey DE, Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-324. 10. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. 11. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-219. 12. Goff Dc Jr Fau - Lloyd-Jones DM, Lloyd-Jones Dm Fau - Bennett G, Bennett G Fau - Coady S, Coady S Fau - D'Agostino RB, Sr., D'Agostino Rb Sr Fau - Gibbons R, Gibbons R Fau - Greenland P, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (1558-3597 (Electronic)). 13. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European Heart Journal. 2003;24(11):987-1003. 14. Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-97. 15. Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006;48(3):374-84. 16. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000;283(15):1967-75. 17. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338. 18. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. The Lancet;366(9489):895-906. 19. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. The Lancet;359(9311):995-1003. 20. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213-25.